Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Arbutus Presents Data from Combination Activity Studies of HBV Drug Candidates

GlobeNewswire April 22, 2016

Arbutus Announces Planned Executive Departure

GlobeNewswire April 21, 2016

Arbutus Presents Data on HBV Capsid Assembly Inhibitor AB-423 at EASL 2016

GlobeNewswire April 14, 2016

Arbutus to Present Preclinical HBV Data at EASL 2016

GlobeNewswire March 30, 2016

Arbutus Announces Year-End 2015 Financial Results

GlobeNewswire March 9, 2016

Arbutus Appoints Dr. Elizabeth Howard Executive Vice President and General Counsel

GlobeNewswire March 8, 2016

Arbutus Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire March 3, 2016

Arbutus Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire February 4, 2016

Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which is Renamed Kuros Biosciences Ltd.

PR Newswire January 20, 2016

Arbutus Provides a Corporate Update and Outlines 2016 Milestones

GlobeNewswire January 10, 2016

Technical Insight on Equity Movement - Research on Ignyta, KongZhong, Arbutus Biopharma and Curis

Accesswire November 25, 2015

Technical Movement Tells the Story - Research on Ignyta, KongZhong, Arbutus Biopharma, and Curis

Accesswire November 17, 2015

Direction of Market Influences - Research on Sodastream International, Digi International, KongZhong and Arbutus Biopharma

Accesswire November 10, 2015

Arbutus Biopharma Announces Third Quarter 2015 Financial Results

GlobeNewswire November 5, 2015

Biotech Bonanza: 4 Stocks With Pending Clinical or Preclinical News (And Why the Results Will Move the Stocks)

Accesswire November 2, 2015

Arbutus Provides an HBV Pipeline Update

GlobeNewswire October 28, 2015

Dr. Michael J. Sofia, Arbutus' Chief Scientific Officer, Named Economist's 2015 Innovation Award Winner in the Bioscience Category

GlobeNewswire October 15, 2015

Arbutus Biopharma Presents Preclinical Data at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses

GlobeNewswire October 6, 2015

Arbutus to Present TKM-HBV Data at the 2015 AASLD Liver Meeting

GlobeNewswire October 1, 2015

Arbutus to Present at the Baird 2015 Healthcare Conference

GlobeNewswire September 9, 2015